Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut

After Repeated Delays, Investors Doubt Readiness

Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.

Novavax
Novavax looks on track to gain an EUA in the US and Europe in early 2022, but may need to develop a new Omicron-targeting version of the vaccine. • Source: Getty Images

Novavax is set to finally gain approval for its much-delayed COVID-19 vaccine, NVX-CoV2373, in key territories in early 2022, but doubts about its manufacturing and the Omicron variant are clouding its outlook.

The recombinant nanoparticle protein-based vaccine will be Novavax’s first ever product on the market and has produced strong trial data,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip